Skip to main content
Canna~Fangled Abstracts

A reliable quantitative method for determining CBD content and release from transdermal patches in Franz cells

By November 12, 2022November 22nd, 2022No Comments

. 2022 Nov 13.

doi: 10.1002/pca.3188.

Online ahead of print.
Liyun Yu 1, Frederikke Bahrt Madsen 1 2, Sofie Helvig Eriksen 1, Aaron J C Andersen 3, Anne Ladegaard Skov 1 2
Affiliations 

Abstract

Introduction: There are several cannabidiol (CBD) transdermal patches available on the market. However, none are FDA-approved. Furthermore, not much evidence has been published about CBD release and skin permeation from such patches, so the effectiveness and reliability remain unclear.

Objectives: We aimed to develop a method to determine the in vitro release and skin permeation of CBD from transdermal patches using Franz cell diffusion in combination with quantitative 1 H-NMR (qNMR).

Materials and methods: The study was conducted on CBD patches with known CBD content and six different commercially available or market-ready CBD patches using a Franz cell with a Strat-M™ membrane and with samples taken directly from the transdermal patch for qNMR analysis.

Results: The use of qNMR yielded an average recovery of 100% ± 7% when samples with known CBD content were tested. Results from the testing of six commercially available patches indicated that five out of six patches did not contain the CBD amount stated by the manufacturer according to a ± 10% variance margin, of which four patches were under-labeled and one was over-labeled. The release rate of patches was determined, and significant differences between the patches were shown. Maximum release of CBD was calculated to occur after 39 to 70 h.

Conclusion: The established method was proven to be a reliable means of determining the quantity and release of CBD from transdermal patches and can be used to verify CBD content and release rate in transdermal patches.

References

REFERENCES

    1. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70:313-318. doi:10.1016/j.yebeh.2016.11.016
    1. Huntsman RJ, Tang-Wai R, Shackelford AE. Cannabis for pediatric epilepsy. J Clin Neurophysiol. 2020;37(1):2-8. doi:10.1097/WNP.0000000000000641
    1. Watt G, Karl T. In vivo evidence for therapeutic properties of Cannabidiol (CBD) for Alzheimer’s disease. Front Pharmacol. 2017;8:20. doi:10.3389/fphar.2017.00020
    1. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of Cannabidiol (CBD): toward a new age. Front Immunol. 2018;9:2009. doi:10.3389/fimmu.2018.02009
    1. Zuardi AW, Crippa JAS, Hallak JEC, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23(8):979-983. doi:10.1177/0269881108096519

LinkOut – more resources

  • Full Text Sources

Leave a Reply